Oct 7 2010
CYTOGENIX, INC. (CYGX.PK-News) announced today that it has engaged the Hall Group, P.C. of Dallas, Texas, to conduct the necessary financial audits to bring CytoGenix, Inc. current on all of its required SEC filings and enable it to move onto the NASDAQ.
Lex Cowsert, CytoGenix's CEO, stated, "This is a critical step necessary to build CytoGenix into a diversified company, while we continue to enter new, global, revenue generating markets. CytoGenix is on a path to become a world class drug development company using its expanding product line and revolutionary synDNA technology as well as advancing the mission of BioEnergy. We fully expect that being listed on the NASDAQ will enhance an already strong company for the future."